Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Letter to the Editor: HCC surveillance in cirrhosis patients: Is the real-world situation even worse than reported? Hepatology (Baltimore, Md.) Huang, D. Q., Yeo, Y. H., Nguyen, M. H. 2021

Abstract

We read with interest the recent systematic review and meta-analysis by Wolf and colleagues, which reported a pooled estimate for hepatocellular carcinoma (HCC) surveillance of 24.0% for patients with cirrhosis (1). We applaud the authors for performing this comprehensive study on a topic that is not only relevant clinically but also timely, especially with the increasing burden of cirrhosis in recent decades.

View details for DOI 10.1002/hep.31760

View details for PubMedID 33617661